title: [Value of estramustine phosphate in the treatment of estrogen-resistant prostatic adenocarcinoma].
abstract: Estramustine phosphate ( Estracyt ) was used in 32 patients with a mean age of 73 and a half years suffering from oestrogen-resistant carcinoma of the prostate. These carcinomas were advanced and were divided into 26 stage D and 6 stage C. Treatment was given orally at a dose of 600 mg per day. Results were assessed on the basis of reliable subjective and objective selected criteria. Objective responses were obtained in 28,1% of cases and subjective responses in 40.6%. All the patients in whom there was an objective response showed a subjective response. Objective action was more marked on the primary tumour than on metastases. There was a decrease in bone pain, an improvement in general condition and disappearance of dysuria in more than a third of all cases. When there was a response, it always occurred before the end of the 2nd month and was maximal at 3 months. The mean duration of a response was 29.1 months for objective responses and 27.7 months for subjective responses. Survival of patients responding to treatment was markedly longer (by 15 months on average) than in patients who failed to respond. The low level of toxicity of the compound, even after prolonged use, makes its use possible in all patients. Thus Estracyt is felt to have a role in the treatment of the severe forms represented by hormone-resistant carcinomas of the prostate.
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D001859:Bone Neoplasms / Q000556:secondary; D004351:Drug Resistance; D004961:Estramustine / Q000627:therapeutic use*; D004967:Estrogens; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D004967:Estrogens; D009588:Nitrogen Mustard Compounds; D004961:Estramustine
vernacular_title: Intérêt de l'estramustine phosphate dans le traitement des adénocarcinomes prostatiques oestrogéno-résistants.